The rate at which such events occur has been widely debated, in part because the risk/benefit ratio of statins in low-risk populations is highly dependent on the rate of adverse events.
A taxa á que ocorren ditos eventos foi moi debatida, en parte porque a razón risco/beneficio das estatinas en poboacións de baixo risco é moi dependente da taxa de episodios adversos.